Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in NuvaRing, is a combined estrogen‑progestogen contraceptive presented as a vaginal ring that releases 0.02 mg/day ethynylestradiol and 0.015 mg/day etonogestrel for vaginal use. The device provides continuous hormone delivery to prevent pregnancy in women of reproductive age.

GNH USA supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing quality‑assured access to this hormonal contraceptive through regulated distribution channels.

NuvaRing, a combined estrogen‑progestogen contraceptive, is used in hormonal regulation to prevent pregnancy. - Prevention of pregnancy: provides reliable, reversible birth control for women of reproductive age.

NuvaRing may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Vaginal irritation or discharge: mild irritation, itching, or increased discharge at the site of insertion. - Headache: transient headaches of mild to moderate intensity. - Nausea: occasional stomach upset or feeling of nausea. - Breast tenderness: mild swelling or tenderness of the breasts. - Irregular bleeding: spotting or breakthrough bleeding between cycles.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis, pulmonary embolism, or stroke. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic adenoma: benign liver tumor, rarely reported.

When prescribing NuvaRing, clinicians should consider several safety precautions to minimize risks. - Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used by pregnant women. - Avoid in smokers over 35 years: increased risk of cardiovascular events. - Screen for thromboembolic history: do not use in women with a history of clotting disorders. - Monitor blood pressure: hormonal contraceptives may elevate blood pressure. - Assess liver function: severe hepatic disease may affect hormone metabolism. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

NuvaRing can interact with other medicines that alter hormone metabolism or affect its efficacy.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s wort): significantly reduce hormone levels, risking contraceptive failure. - Protease inhibitors (e.g., ritonavir): may lower contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole, itraconazole): may increase hormone concentrations, heightening side‑effect risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may slightly increase bleeding tendency. - Certain antibiotics (e.g., tetracycline): may modestly reduce contraceptive efficacy.